Neurocrine Biosciences, Inc. (NBIX) Presents at Piper Sandler thirty seventh Annual Healthcare Convention Transcript

David Amsellem
Piper Sandler & Co., Analysis Division

Properly, let’s kick issues off. That is David Amsellem from the Piper Sandler biopharma analysis workforce. We’re delighted to have Neurocrine right here. We’ve got Matt Abernethy, CFO. We’ve got Eric Benevich, Chief Business Officer. We’ve got Todd Tushla, director of Investor Relations. Thanks, gents, for becoming a member of us.

So it has been fairly a 12 months. So I’d love to show it over to Matt for just some opening remarks on, I assume, a mirrored image on what’s been to say the least, an fascinating 12 months, each for Neurocrine and for the biotech house, we’re at massive.

Matthew Abernethy
Chief Monetary Officer

Properly, I like the way you mentioned delighted to have us right here. I feel this 12 months, anyone who thinks it has been a delight, I feel, is fooling themselves. I used to be speaking to investor earlier than this, they usually had been reflecting on we’re sitting right here in a very good house — spot from a inventory efficiency, however getting right here, man, it has been a slog, I feel, for your complete business. So I feel that there is a lot happening within the business and within the sector. After which for us, as an organization, we’re really executing fairly effectively. I feel you’d agree with that.

It’s early. It’s 6:30 a.m. again in California. And so I assumed perhaps I would share just a little bit about what motivated me to get off the bed this morning and what motivates us to get off the bed each single morning. The three issues that come prime of thoughts